Developer docs
API playgroundTry for free, no card

Search company profiles

Dalton Pharma Services

Full company profile

uuid0007jj8

Namestring
Dalton Pharma Services
Legal namestring
Dalton Pharma Services
Websiteurl
dalton.com
Company typeenum
Private
Founded yearint
1986
Descriptiontext

Dalton Pharma Services is a Toronto, Canada-based Contract Development and Manufacturing Organization (CDMO) that has operated from a single integrated site since its 1986 founding at York University. The company provides pharmaceutical and biotechnology clients with a full lifecycle offering spanning medicinal chemistry, drug discovery, custom chemical synthesis, API process development, cGMP API manufacturing (gram to multi-kilogram scale, reactors up to 300L), formulation development (including liposomes, sterile liquids, and lyophilized forms), cGMP sterile fill/finish, and in-house analytical and microbiological testing under a unified Quality Management System. The platform includes specialized capabilities for controlled substances, oligonucleotides, antibody-drug conjugates, nanoparticles, and cannabinoids.

The company's technical differentiators include the proprietary RoboFil™ robotic isolator-based aseptic powder fill-finish system (developed with 3P innovation and using Fill2Weight technology with ±3% dosing accuracy from 5 mg to 1000 mg), the Capmatic Patriot® automated sterile vial filling line (~40 BPM), a cGMP lyophilizer, and advanced analytical instrumentation including SEC-MALS, ICP-MS (Agilent 7800), and UPLC. Regulatory credentials include FDA inspection, Health Canada approval (Drug Establishment Licence plus three cannabis-related licences), ICH Q3D/Q7/Q1B compliance, Annex 1 alignment, and planned ISO 13485 certification. The business model is project-based contract services with quote-driven pricing, RFP submissions, and direct enterprise business development; complementary product revenue comes from a 2,600+ compound catalog via wholly-owned subsidiary Dalton Research Molecules. Dalton is a privately held subsidiary of Japan's Seikagaku Group, with leadership under CEO Peter Pekos and President Dr. Jixing Wang.

Short descriptiontext

Dalton Pharma Services is a Toronto-based, FDA-inspected and Health Canada-approved cGMP CDMO providing integrated drug discovery, API manufacturing, formulation, and sterile fill/finish services to pharmaceutical and biotechnology clients globally. It is a wholly-owned subsidiary of Japan's Seikagaku Group and operates proprietary robotic aseptic powder fill-finish technology.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract pharmaceutical manufacturing, cGMP API manufacturing, sterile fill-finish services, drug discovery development, analytical testing laboratory
Industry5 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code4 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
  • Medicinal and Botanical Manufacturing325411
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code4 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
  • Medicinal Chemicals & Botanical Products2833
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceutical CDMO Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Development and Manufacturing Services (CDMO)
TypeOthers
Description

Dalton Pharma Services generates revenue by providing integrated pharmaceutical development and manufacturing services on a contract project basis. Services include custom chemical synthesis, cGMP API manufacturing, sterile fill/finish, formulation development, and analytical testing. Revenue is project-based with quotes provided for each engagement. The company does not publicly disclose pricing and operates on a quote-based/procurement model typical of CDMOs.

dalton.com
2Chemical Compounds Catalog (Dalton Research Molecules)
TypeOthers
Description

A wholly owned subsidiary, Dalton Research Molecules, provides high-quality chemical compounds for research purposes, including building blocks, drugs, metabolites, and controlled substances. The catalog contains over 2,600 compounds and continues to grow.

dalton.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Pricing details1 tier
1Project-based contract services — no public pricing tiers; all engagements quoted individually based on project scope.
ModelOtherBilling cadenceMulti-year contract
Notes

Services are provided on a project-by-project basis via RFP/quote model. No public pricing is listed. Clients submit project requirements through the company's RFP form or via discovery calls/virtual meetings.

dalton.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Steriles Made Simple℠
Description

Accelerated clinical sterile vial manufacturing program delivering sterile injectable dosage forms in approximately 4 months

dalton.com
+1 more record
Core offering1 text field

Dalton Pharma Services is a Contract Development and Manufacturing Organization (CDMO) that delivers integrated drug discovery, pharmaceutical development, and cGMP manufacturing services from a single FDA-inspected, Health Canada-approved facility in Toronto. Services include custom chemical synthesis, API process development, cGMP API manufacturing, formulation development, sterile and aseptic fill-finish (liquid and powder), and contract analytical testing, complemented by a wholly owned chemical compound catalog under Dalton Research Molecules.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 99.3%+ API purity achieved in multi-kilogram scale-up campaigns for Onco-Innovations' ONC010 drug candidate
+3 more records
Product overview1 text field

Dalton Pharma Services is a Contract Development and Manufacturing Organization (CDMO) providing integrated pharmaceutical services from drug discovery through commercial manufacturing. The company operates as a single-site model integrating API development, cGMP manufacturing, formulation, aseptic fill/finish, and in-house QC/microbiological testing. Key services include Drug Discovery & Development Services, cGMP API Manufacturing, cGMP Sterile Filling Services (including Steriles Made Simple℠ program), Custom Chemical Synthesis, API Process Development, Formulation Development (including Liposomal Formulations), Contract Analytical Testing Laboratory, Medicinal Chemistry, Accelerated Stability Testing, Polymorphic Screening, Conjugation Services, and Microbiology Services. The company offers specialized capabilities including GMP Oligonucleotide Fill, Extractables & Leachables Testing, ICP-MS Elemental Analysis, UPLC Analysis, and SEC-MALS Services. Advanced equipment includes the Capmatic Patriot® automated vial filling line and RoboFil™ robotic aseptic powder fill-finish system. A chemical compound catalog (Dalton Research Molecules) with over 2,600 products is available through a subsidiary.

Product and service12 records
1Drug Discovery & Development Services
CategoryDrug Discovery & Development
Description

Integrated drug discovery and development services featuring synthetic feasibility, scale-up, process development, lead optimization, drug analog synthesis, and structure activity optimization for pharmaceutical and biotechnology clients.

2cGMP API Manufacturing
CategorycGMP API Manufacturing
Description

Development and manufacture of complex cGMP Active Pharmaceutical Ingredients from grams to multi-kilograms, supporting preclinical through small-scale commercial manufacturing with reactor sizes up to 300L.

3cGMP Sterile Filling Services
CategorySterile Fill-Finish Services
Description

Aseptic and terminally sterilized cGMP filling services for clinical through small-scale commercial batches, including liquid injectables and sterile powder filling supported by the RoboFil™ robotic isolator platform and the Capmatic Patriot® automated vial filling line.

4Custom Chemical Synthesis
CategoryCustom Synthesis
Description

Custom synthesis of low volume, high value small molecules including active pharmaceutical ingredients, pharmaceutical intermediates, drug metabolites, drug analogs, analytical standards, and controlled substances, for biotechnology and pharmaceutical applications.

5API Process Development
CategoryAPI Process Development
Description

API process development services including optimization of synthetic routes, identification of GMP-friendly alternative routes, statistical Design of Experiments (DoE) for process parameterization, and documentation of CMC development projects.

6Formulation Development
CategoryFormulation Development
Description

Sterile and non-sterile dosage form development including oral immediate release, sterile liquids, powders, injectables, and lyophilized formulations.

7Contract Analytical Testing Laboratory
CategoryAnalytical Testing Services
Description

Comprehensive analytical services including method development and validation, raw material release testing, in-process testing, finished product release testing, and ICH-compliant accelerated, intermediate, and long-term stability testing.

8Medicinal Chemistry
CategoryDrug Discovery Chemistry
Description

Drug discovery and design services including structure-based analog design, synthetic organic chemistry, focused library synthesis, and structure-activity relationship (SAR) elucidation.

9Steriles Made Simple℠ Accelerated Clinical Vial Program
CategoryClinical Sterile Manufacturing Service
Description

Accelerated development program delivering sterile injectable dosage forms into clinic faster using in-stock vial container closure options and commonly used excipients, completing API receipt to clinical batch delivery in approximately 4 months.

10Liposomal Formulations Development
CategoryLiposomal / Complex Drug Delivery
Description

Complex liposomal formulation development and manufacturing with small molecules, proteins, and peptides, including both aseptic and terminally sterilized options, supported by more than 10 years of specialized experience.

11GMP Oligonucleotide Aseptic Filling
CategoryOligonucleotide Aseptic Fill-Finish
Description

GMP aseptic filling of oligonucleotide drug products using peristaltic filling equipment to minimize hold-up volumes and preserve valuable APIs across clinical batches.

12Dalton Research Molecules Chemical Compound Catalog
CategoryChemical Catalog / Product Sales
Description

Catalog of more than 2,600 high-quality chemical compounds for research purposes, including building blocks, drugs and metabolites, heterocycles, natural compounds, labelled compounds, peptides, nucleic acids, organometallics, controlled drugs, and GMP APIs/excipients/adjuvants, sold via the Dalton Research Molecules online catalog.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-09
Description

Onco-Innovations partnered with Dalton Pharma Services as its manufacturing partner for its proprietary PNKP inhibitor technology (ONC010), including API process development, intermediate scale-up, and multi-kilogram synthesis campaigns. Work supports IND-enabling studies and Phase 1 clinical readiness. Dalton has conducted expanded synthesis of ~1,560g of precursor A83, a 2kg non-GMP synthesis of A83B4C63, a 952g B4 precursor scale-up, and a 300g API scale-up achieving ~99.3% purity. Manufacturing conducted at Dalton's FDA-registered and Health Canada-approved Toronto facility.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-02
Description

Dalton Pharma Services supports Vimy Pharmaceuticals, a Toronto-based company developing a made-in-Canada generic version of Semaglutide (Ozempic) for the Canadian market. Dalton provides regulatory-focused formulation development and cGMP manufacturing to support Health Canada approval and 2026 target launch. Featured in BNN Bloomberg interview discussing Canada's pharmaceutical manufacturing capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-27
Description

Arch Biopartners engaged Dalton Pharma Services to complete GMP glass vial filling of cilastatin, the company's drug candidate for preventing acute kidney injury (AKI). Dalton completed the filling stage with quality control over 6-8 weeks. Previously, Dalton provided fill and finish services for Arch's LSALT Peptide (Metablok) which entered the Canadian COVID-19 Trial (CATCO).

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-06-05
Description

Dalton Pharma Services commissioned 3P innovation (Warwick, UK) to design and construct a fully automated state-of-the-art high-speed aseptic powder filling line (RoboFil™). The Robotic Fill-Finish (RFF) Cell from 3P innovation was selected based on feasibility studies of difficult-to-handle powders, increased sterility assurance, and Annex 1 compliance. The multi-year association resulted in a bespoke integrated solution with isolators and linked process chambers.

5TransMedics Group Inc.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-26
Description

Dalton Pharma Services entered a manufacturing agreement with TransMedics to provide powder filling services in the manufacture of the OCS Liver System, which received FDA premarket approval for portable ex-vivo perfusion and assessment of donor organs for transplantation. TransMedics achieved FDA approval for lung, heart, and liver OCS systems, with Dalton supporting commercialization.

dalton.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-27
Description

Dalton Pharma Services has an exclusive worldwide partnership with Diamond Therapeutics to provide cGMP psilocybin and other compounds to support clinical trials, research, and future commercial opportunities. Dalton is one of only a few Canadian companies to successfully manufacture cGMP psilocybin for regulatory submissions. Material already produced is sufficient for Diamond's clinical trial needs in the US and Canada.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-10-20
Description

Dalton Pharma Services is the exclusive manufacturer of Cortalex™ THC-free extra-strength (100 mg/mL) oral CBD formulation for Cardiol Therapeutics. Cortalex™ is the first pharmaceutically produced CBD formulated without THC, available exclusively at Medical Cannabis by Shoppers Drug Mart across Canada. Dalton's Health Canada-approved, FDA-registered cGMP facilities ensure consistent composition and THC-free quality.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Through its Patheon CDMO business, Thermo Fisher offers integrated API, oral solid dose, sterile fill-finish, and clinical trial material services; directly overlaps with Dalton's integrated CDMO model but at global scale with commercial manufacturing depth.

TypeBroad incumbent
Description

Large global CDMO offering comprehensive drug development, biologics, and sterile fill-finish services across dozens of facilities; overlaps with Dalton's aseptic fill-finish and formulation development offerings but operates at much greater scale and breadth.

TypeOthers
Description

Global CDMO leader offering small-molecule API, biologics manufacturing, and sterile fill-finish; comparable in API manufacturing and aseptic services but at vastly larger scale and with broader modality coverage including cell and gene therapies.

TypeEmerging player
Description

Specialty CDMO focused on aseptic fill-finish of live viral vaccines and viral vectors; comparable to Dalton in GMP aseptic fill-finish for advanced modalities though narrower in modality scope and more focused on viral-based therapeutics.

TypeBroad incumbent
Description

Global CDMO focused on clinical and commercial sterile fill-finish, packaging, and serialization; comparable to Dalton in sterile injectable capabilities but with broader geographic footprint and integrated packaging specialization.

6Recipharm
TypeBroad incumbent
Description

European-headquartered CDMO offering sterile fill-finish, API manufacturing, and development services; comparable to Dalton's integrated CDMO model though focused more on biologics and with a predominantly European geographic footprint.

TypeBroad incumbent
Description

Global CDMO offering API development, sterile manufacturing, and antibody-drug conjugation services across multiple sites; comparable to Dalton in sterile fill-finish and high-potency API capabilities, particularly in ADC conjugation.

TypeDirect peer
Description

Privately-held mid-sized CDMO specializing in integrated API development, particle engineering, and aseptic fill-finish for small molecules. Comparable to Dalton in integrated single-site model, small-molecule focus, and mid-market positioning serving biotech clients.

TypeDirect peer
Description

Global CDMO offering integrated API manufacturing, formulation, and aseptic fill-finish across multiple sites; comparable to Dalton in providing end-to-end contract manufacturing from API to sterile drug product for biotech and pharma clients.

TypeDirect peer
Description

Mid-sized US-based CDMO providing API development, sterile fill-finish, and analytical services; directly comparable to Dalton in offering integrated contract development and small-batch sterile manufacturing for small and mid-cap pharma/biotech.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance12 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Dalton Pharma Services

Pharmaceutical CDMO Servicesdalton.com

Dalton Pharma Services is a Toronto-based, FDA-inspected and Health Canada-approved cGMP CDMO providing integrated drug discovery, API manufacturing, formulation, and sterile fill/finish services to pharmaceutical and biotechnology clients globally. It is a wholly-owned subsidiary of Japan's Seikagaku Group and operates proprietary robotic aseptic powder fill-finish technology.

What Dalton Pharma Services does

Dalton Pharma Services is a Toronto, Canada-based Contract Development and Manufacturing Organization (CDMO) that has operated from a single integrated site since its 1986 founding at York University. The company provides pharmaceutical and biotechnology clients with a full lifecycle offering spanning medicinal chemistry, drug discovery, custom chemical synthesis, API process development, cGMP API manufacturing (gram to multi-kilogram scale, reactors up to 300L), formulation development (including liposomes, sterile liquids, and lyophilized forms), cGMP sterile fill/finish, and in-house analytical and microbiological testing under a unified Quality Management System. The platform includes specialized capabilities for controlled substances, oligonucleotides, antibody-drug conjugates, nanoparticles, and cannabinoids.

The company's technical differentiators include the proprietary RoboFil™ robotic isolator-based aseptic powder fill-finish system (developed with 3P innovation and using Fill2Weight technology with ±3% dosing accuracy from 5 mg to 1000 mg), the Capmatic Patriot® automated sterile vial filling line (~40 BPM), a cGMP lyophilizer, and advanced analytical instrumentation including SEC-MALS, ICP-MS (Agilent 7800), and UPLC. Regulatory credentials include FDA inspection, Health Canada approval (Drug Establishment Licence plus three cannabis-related licences), ICH Q3D/Q7/Q1B compliance, Annex 1 alignment, and planned ISO 13485 certification. The business model is project-based contract services with quote-driven pricing, RFP submissions, and direct enterprise business development; complementary product revenue comes from a 2,600+ compound catalog via wholly-owned subsidiary Dalton Research Molecules. Dalton is a privately held subsidiary of Japan's Seikagaku Group, with leadership under CEO Peter Pekos and President Dr. Jixing Wang.

Dalton Pharma Services firmographics

Firmographics
Name
Dalton Pharma Services
Legal name
Dalton Pharma Services
Website
https://dalton.com
Company type
Private
Founded year
1986
Operating status
Operating
Headcount range
101–250 employees
Short description
Dalton Pharma Services is a Toronto-based, FDA-inspected and Health Canada-approved cGMP CDMO providing integrated drug discovery, API manufacturing, formulation, and sterile fill/finish services to pharmaceutical and biotechnology clients globally. It is a wholly-owned subsidiary of Japan's Seikagaku Group and operates proprietary robotic aseptic powder fill-finish technology.
Ownership category
akta.pro rank

Dalton Pharma Services industry classification

Industry
Product category
Pharmaceutical CDMO Services
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Contract pharmaceutical manufacturing
  • CGMP API manufacturing
  • Sterile fill-finish services
  • Drug discovery development
  • Analytical testing laboratory

Where Dalton Pharma Services is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Dalton Pharma Services business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Development and Manufacturing Services (CDMO): Dalton Pharma Services generates revenue by providing integrated pharmaceutical development and manufacturing services on a contract project basis. Services include custom chemical synthesis, cGMP API manufacturing, sterile fill/finish, formulation development, and analytical testing. Revenue is project-based with quotes provided for each engagement. The company does not publicly disclose pricing and operates on a quote-based/procurement model typical of CDMOs.
  2. Chemical Compounds Catalog (Dalton Research Molecules): A wholly owned subsidiary, Dalton Research Molecules, provides high-quality chemical compounds for research purposes, including building blocks, drugs, metabolites, and controlled substances. The catalog contains over 2,600 compounds and continues to grow.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based contract services — no public pricing tiers; all engagements quoted individually based on project scope.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Dalton Pharma Services product offering

Product offering

Core offering

Dalton Pharma Services is a Contract Development and Manufacturing Organization (CDMO) that delivers integrated drug discovery, pharmaceutical development, and cGMP manufacturing services from a single FDA-inspected, Health Canada-approved facility in Toronto. Services include custom chemical synthesis, API process development, cGMP API manufacturing, formulation development, sterile and aseptic fill-finish (liquid and powder), and contract analytical testing, complemented by a wholly owned chemical compound catalog under Dalton Research Molecules.

Product overview

Dalton Pharma Services is a Contract Development and Manufacturing Organization (CDMO) providing integrated pharmaceutical services from drug discovery through commercial manufacturing. The company operates as a single-site model integrating API development, cGMP manufacturing, formulation, aseptic fill/finish, and in-house QC/microbiological testing. Key services include Drug Discovery & Development Services, cGMP API Manufacturing, cGMP Sterile Filling Services (including Steriles Made Simple℠ program), Custom Chemical Synthesis, API Process Development, Formulation Development (including Liposomal Formulations), Contract Analytical Testing Laboratory, Medicinal Chemistry, Accelerated Stability Testing, Polymorphic Screening, Conjugation Services, and Microbiology Services. The company offers specialized capabilities including GMP Oligonucleotide Fill, Extractables & Leachables Testing, ICP-MS Elemental Analysis, UPLC Analysis, and SEC-MALS Services. Advanced equipment includes the Capmatic Patriot® automated vial filling line and RoboFil™ robotic aseptic powder fill-finish system. A chemical compound catalog (Dalton Research Molecules) with over 2,600 products is available through a subsidiary.

Differentiator

Problem solved

Functional benefit

Brands

  • Steriles Made Simple℠: Accelerated clinical sterile vial manufacturing program delivering sterile injectable dosage forms in approximately 4 months
  • RoboFil™

Products and services

  • Drug Discovery & Development Services Integrated drug discovery and development services featuring synthetic feasibility, scale-up, process development, lead optimization, drug analog synthesis, and structure activity optimization for pharmaceutical and biotechnology clients.
  • cGMP API Manufacturing Development and manufacture of complex cGMP Active Pharmaceutical Ingredients from grams to multi-kilograms, supporting preclinical through small-scale commercial manufacturing with reactor sizes up to 300L.
  • cGMP Sterile Filling Services Aseptic and terminally sterilized cGMP filling services for clinical through small-scale commercial batches, including liquid injectables and sterile powder filling supported by the RoboFil™ robotic isolator platform and the Capmatic Patriot® automated vial filling line.
  • Custom Chemical Synthesis Custom synthesis of low volume, high value small molecules including active pharmaceutical ingredients, pharmaceutical intermediates, drug metabolites, drug analogs, analytical standards, and controlled substances, for biotechnology and pharmaceutical applications.
  • API Process Development API process development services including optimization of synthetic routes, identification of GMP-friendly alternative routes, statistical Design of Experiments (DoE) for process parameterization, and documentation of CMC development projects.
  • Formulation Development Sterile and non-sterile dosage form development including oral immediate release, sterile liquids, powders, injectables, and lyophilized formulations.
  • Contract Analytical Testing Laboratory Comprehensive analytical services including method development and validation, raw material release testing, in-process testing, finished product release testing, and ICH-compliant accelerated, intermediate, and long-term stability testing.
  • Medicinal Chemistry Drug discovery and design services including structure-based analog design, synthetic organic chemistry, focused library synthesis, and structure-activity relationship (SAR) elucidation.
  • Steriles Made Simple℠ Accelerated Clinical Vial Program Accelerated development program delivering sterile injectable dosage forms into clinic faster using in-stock vial container closure options and commonly used excipients, completing API receipt to clinical batch delivery in approximately 4 months.
  • Liposomal Formulations Development Complex liposomal formulation development and manufacturing with small molecules, proteins, and peptides, including both aseptic and terminally sterilized options, supported by more than 10 years of specialized experience.
  • GMP Oligonucleotide Aseptic Filling GMP aseptic filling of oligonucleotide drug products using peristaltic filling equipment to minimize hold-up volumes and preserve valuable APIs across clinical batches.
  • Dalton Research Molecules Chemical Compound Catalog Catalog of more than 2,600 high-quality chemical compounds for research purposes, including building blocks, drugs and metabolites, heterocycles, natural compounds, labelled compounds, peptides, nucleic acids, organometallics, controlled drugs, and GMP APIs/excipients/adjuvants, sold via the Dalton Research Molecules online catalog.

Quantifiable outcome

  • 99.3%+ API purity achieved in multi-kilogram scale-up campaigns for Onco-Innovations' ONC010 drug candidate
  • +3 more outcomes

Companies that use Dalton Pharma Services

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Dalton Pharma Services technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Dalton Pharma Services partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core.

  • Onco-Innovations LimitedcoreStrategic or Co-development Partner · 9 June 2026Onco-Innovations partnered with Dalton Pharma Services as its manufacturing partner for its proprietary PNKP inhibitor technology (ONC010), including API process development, intermediate scale-up, and multi-kilogram synthesis campaigns. Work supports IND-enabling studies and Phase 1 clinical readiness. Dalton has conducted expanded synthesis of ~1,560g of precursor A83, a 2kg non-GMP synthesis of A83B4C63, a 952g B4 precursor scale-up, and a 300g API scale-up achieving ~99.3% purity. Manufacturing conducted at Dalton's FDA-registered and Health Canada-approved Toronto facility.
  • Vimy Pharmaceuticals Inc.coreStrategic or Co-development Partner · 2 October 2025Dalton Pharma Services supports Vimy Pharmaceuticals, a Toronto-based company developing a made-in-Canada generic version of Semaglutide (Ozempic) for the Canadian market. Dalton provides regulatory-focused formulation development and cGMP manufacturing to support Health Canada approval and 2026 target launch. Featured in BNN Bloomberg interview discussing Canada's pharmaceutical manufacturing capabilities.
  • Arch Biopartners Inc.coreStrategic or Co-development Partner · 27 June 2024Arch Biopartners engaged Dalton Pharma Services to complete GMP glass vial filling of cilastatin, the company's drug candidate for preventing acute kidney injury (AKI). Dalton completed the filling stage with quality control over 6-8 weeks. Previously, Dalton provided fill and finish services for Arch's LSALT Peptide (Metablok) which entered the Canadian COVID-19 Trial (CATCO).
  • 3P innovationcoreTechnology or Integration · 5 June 2024Dalton Pharma Services commissioned 3P innovation (Warwick, UK) to design and construct a fully automated state-of-the-art high-speed aseptic powder filling line (RoboFil™). The Robotic Fill-Finish (RFF) Cell from 3P innovation was selected based on feasibility studies of difficult-to-handle powders, increased sterility assurance, and Annex 1 compliance. The multi-year association resulted in a bespoke integrated solution with isolators and linked process chambers.
  • TransMedics Group Inc.coreStrategic or Co-development Partner · 26 October 2021Dalton Pharma Services entered a manufacturing agreement with TransMedics to provide powder filling services in the manufacture of the OCS Liver System, which received FDA premarket approval for portable ex-vivo perfusion and assessment of donor organs for transplantation. TransMedics achieved FDA approval for lung, heart, and liver OCS systems, with Dalton supporting commercialization.
  • Diamond Therapeutics Inc.coreStrategic or Co-development Partner · 27 July 2021Dalton Pharma Services has an exclusive worldwide partnership with Diamond Therapeutics to provide cGMP psilocybin and other compounds to support clinical trials, research, and future commercial opportunities. Dalton is one of only a few Canadian companies to successfully manufacture cGMP psilocybin for regulatory submissions. Material already produced is sufficient for Diamond's clinical trial needs in the US and Canada.
  • Cardiol Therapeutics Inc.coreStrategic or Co-development Partner · 20 October 2020Dalton Pharma Services is the exclusive manufacturer of Cortalex™ THC-free extra-strength (100 mg/mL) oral CBD formulation for Cardiol Therapeutics. Cortalex™ is the first pharmaceutically produced CBD formulated without THC, available exclusively at Medical Cannabis by Shoppers Drug Mart across Canada. Dalton's Health Canada-approved, FDA-registered cGMP facilities ensure consistent composition and THC-free quality.

Scale indicators7 records

Recent moves9 records

Expansion highlights7 records

Dalton Pharma Services competitors and assessment

Company assessment

Broad incumbents

  • Thermo Fisher Scientific (Patheon): Through its Patheon CDMO business, Thermo Fisher offers integrated API, oral solid dose, sterile fill-finish, and clinical trial material services; directly overlaps with Dalton's integrated CDMO model but at global scale with commercial manufacturing depth.
  • Catalent: Large global CDMO offering comprehensive drug development, biologics, and sterile fill-finish services across dozens of facilities; overlaps with Dalton's aseptic fill-finish and formulation development offerings but operates at much greater scale and breadth.
  • PCI Pharma Services: Global CDMO focused on clinical and commercial sterile fill-finish, packaging, and serialization; comparable to Dalton in sterile injectable capabilities but with broader geographic footprint and integrated packaging specialization.
  • Recipharm: European-headquartered CDMO offering sterile fill-finish, API manufacturing, and development services; comparable to Dalton's integrated CDMO model though focused more on biologics and with a predominantly European geographic footprint.
  • Piramal Pharma Solutions: Global CDMO offering API development, sterile manufacturing, and antibody-drug conjugation services across multiple sites; comparable to Dalton in sterile fill-finish and high-potency API capabilities, particularly in ADC conjugation.

Others

  • Lonza: Global CDMO leader offering small-molecule API, biologics manufacturing, and sterile fill-finish; comparable in API manufacturing and aseptic services but at vastly larger scale and with broader modality coverage including cell and gene therapies.

Emerging players

  • Vibalogics: Specialty CDMO focused on aseptic fill-finish of live viral vaccines and viral vectors; comparable to Dalton in GMP aseptic fill-finish for advanced modalities though narrower in modality scope and more focused on viral-based therapeutics.

Direct peers

  • Hovione: Privately-held mid-sized CDMO specializing in integrated API development, particle engineering, and aseptic fill-finish for small molecules. Comparable to Dalton in integrated single-site model, small-molecule focus, and mid-market positioning serving biotech clients.
  • CordenPharma: Global CDMO offering integrated API manufacturing, formulation, and aseptic fill-finish across multiple sites; comparable to Dalton in providing end-to-end contract manufacturing from API to sterile drug product for biotech and pharma clients.
  • Alcami Corporation: Mid-sized US-based CDMO providing API development, sterile fill-finish, and analytical services; directly comparable to Dalton in offering integrated contract development and small-batch sterile manufacturing for small and mid-cap pharma/biotech.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Dalton Pharma Services social profiles

Digital presence

Dalton Pharma Services compliance and trust

Trust signal

Compliance12 records

Dalton Pharma Services financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Dalton Pharma Services leadership team

Management profile

Number of profiles

Profiles5 records

Dalton Pharma Services subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Dalton Pharma Services funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Dalton Pharma Services M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dalton Pharma Services

What does Dalton Pharma Services do?

Dalton Pharma Services is a Contract Development and Manufacturing Organization (CDMO) that delivers integrated drug discovery, pharmaceutical development, and cGMP manufacturing services from a single FDA-inspected, Health Canada-approved facility in Toronto. Services include custom chemical synthesis, API process development, cGMP API manufacturing, formulation development, sterile and aseptic fill-finish (liquid and powder), and contract analytical testing, complemented by a wholly owned chemical compound catalog under Dalton Research Molecules.

Is Dalton Pharma Services a public or private company?

Dalton Pharma Services is a private company. It is classified as corporate owned and is currently operating.

When was Dalton Pharma Services founded?

Dalton Pharma Services was founded in 1986. It employs 101 to 250 people.

Where is Dalton Pharma Services based?

Dalton Pharma Services is headquartered in Toronto, Canada, in the North America region.

How does Dalton Pharma Services make money?

Two revenue lines are on record. Contract Development and Manufacturing Services (CDMO) is the primary driver. The others are chemical Compounds Catalog (Dalton Research Molecules).

Who are Dalton Pharma Services's main competitors?

Broad incumbents on record are Thermo Fisher Scientific (Patheon), Catalent, PCI Pharma Services, Recipharm and Piramal Pharma Solutions. Lonza is listed as an others. Vibalogics is listed as an emerging player. Direct peers are Hovione, CordenPharma and Alcami Corporation.

Does Dalton Pharma Services have an API?

No public API is recorded for Dalton Pharma Services.

What industry is Dalton Pharma Services in?

Dalton Pharma Services's product category is Pharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAA, Small-Molecule API & Intermediates CDMO. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MorningstarOnco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010’s APIOnco-Innovations completed its analytical reference standard preparation program for A83B4C63, the API for its lead oncology program ONC010. The program, done with Dalton Pharma Services, includes preparation, purification, and quality assessment of the material. It supports future manufacturing and regulatory readiness for ONC010.FinancialContent Business PageNext-Generation DNA Repair Therapies Open New Frontiers in OncologyOnco-Innovations Limited, a Canadian clinical-stage oncology company, is advancing ONC010, a nanoparticle-encapsulated PNKP inhibitor for solid tumors, as part of the expanding DNA Damage Response inhibitor (DDRi) market estimated at over $7 billion in 2025. The company holds exclusive global rights to the PNKP inhibitor technology and reported preclinical data showing its colorectal cancer formulation extended median survival from 23 to 60 days in animal models. Onco-Innovations is executing IND-enabling studies and manufacturing scale-up with partners Dalton Pharma Services and Nucro-Technics, with plans for a first-in-human phase 1 trial anticipated in late 2026, positioning itself as the established first-mover in an uncrowded drug class with no approved competitors.BioSpaceOnco-Innovations Announces Initiation of API Process Development and Intermediate Scale-Up Program for its Proprietary PNKP Inhibitor TechnologyOnco-Innovations announced the initiation of process development and intermediate scale-up for its API A83B4C63 in drug candidate ONC010. The program, with Dalton Pharma Services, aims to optimize synthetic processes and scale production for preclinical and clinical supply. The work supports IND-enabling studies and First-in-Human planning.BioSpaceOnco-Innovations Reports Continued Advancement of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for ONC010 Development ProgramOnco-Innovations reported continued progress in intermediate-scale synthesis of A83 and B4 precursor components for its ONC010 nanoparticle PNKP inhibitor. The work, done with Dalton Pharma Services, showed encouraging purity and reproducibility, supporting future GMP production and First-in-Human clinical development in Australia.BioSpaceOnco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling StudiesOnco-Innovations announced Dalton Pharma Services advanced its PNKP inhibitor manufacturing, scaling precursor A83 to 1,560 grams and initiating a 2-kilogram non-GMP synthesis of A83B4C63. The work supports IND-enabling studies and formulation development, with stability and analytical characterization aligned to ICH expectations.FinancialContent Business PageOnco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling StudiesOnco-Innovations Limited has expanded its manufacturing partnership with Dalton Pharma Services to advance scale-up of its PNKP inhibitor technology, including production of approximately 1,560 grams of precursor A83 and initiation of a 2 kg non-GMP synthesis of A83B4C63. The work at Dalton's FDA-registered and Health Canada-approved facility in Toronto is intended to support IND-enabling studies and future Phase I clinical readiness under Chemistry, Manufacturing, and Controls development requirements. The company also extended its market awareness engagement with MCS Market Communication Service GmbH for €210,000 through July 2026.PR NewswireDalton Pharma Services Expands Aseptic Powder Fill-Finish Capacity with RoboFil™ system in TorontoDalton Pharma Services announced the successful installation of its RoboFil™ aseptic powder fill-finish system at its Toronto, Canada facility, expanding its aseptic fill-finish capacity with a fully automated, isolator-based platform. The system combines robotic handling with isolator technology to minimize contamination risk through reduced operator interventions while enabling rapid changeovers between vial formats. The platform supports both early-stage clinical supply manufacturing through to scalable commercial GMP production and is aligned with Annex 1 regulatory requirements.YahooDalton Pharma Services Expands Aseptic Powder Fill-Finish Capacity with RoboFil™ system in TorontoDalton Pharma Services announced the installation of its RoboFil™ aseptic powder fill-finish system at its Toronto, Canada facility, a fully automated, isolator-based platform. The system combines robotic handling with isolator technology to minimize contamination risks while enabling rapid changeovers between vial formats, supporting programs from early clinical supply through scalable commercial manufacturing. This expansion strengthens Dalton's position as a market leader in aseptic fill-finish services for biotech and pharmaceutical companies.YahooDalton Pharma Services Expands Aseptic Powder Fill-Finish Capacity with RoboFil™ system in TorontoDalton Pharma Services announced the successful installation of its RoboFil™ aseptic powder fill-finish system at its Toronto, Canada facility on March 31, 2026. The fully automated, isolator-based platform combines robotic handling with isolator technology to minimize contamination risks from operator interventions while enabling rapid changeovers between vial formats. The Annex 1-aligned system expands both the company's aseptic fill-finish capacity and operational flexibility, supporting programs from early clinical supply through scalable commercial GMP production.BioSpaceOnco-Innovations Advances Optimization and Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services to Support Future Phase 1 Clinical StudiesOnco-Innovations Limited announced that its manufacturing partner Dalton Pharma Services has initiated process optimization and intermediate scale-up activities for A83B4C63, the company's proprietary PNKP Inhibitor Technology, to support future Phase 1 clinical studies. The work includes producing approximately 500g of precursor A83 and 1,000g of precursor B4 under non-GMP conditions at Dalton's FDA- and Health Canada-approved facility in Toronto. This phase is designed to establish a robust, reproducible manufacturing process suitable for future GMP production and clinical trial material.